AmirTFathiMD

Oncology • Boston, MA

Hematologic Oncology

Associate Professor of Medicine, Harvard Medical School -- Director, Leukemia Program, Massachusetts General Hospital

Join to view full profile

Dr. Fathi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Fathi's full profile

Already have an account?

Office
55 Fruit St
Boston, MA 02114
Phone+1 617-724-1124

Fax+1 617-724-1126

Education & Training

Harvard School of Public HealthMasters, Epidemiology, 2012 - 2014
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2007 - 2010
Massachusetts General HospitalResidency, Internal Medicine, 2004 - 2007
Yale School of MedicineClass of 2004
Yale UniversityBS, 1996 - 2000

Certifications & Licensure

MA State Medical License 2006 - 2026
MD State Medical License 2007 - 2010
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Alisertib for Acute Myeloid Leukemia Start of enrollment: 2013 Apr 01
Completed
Phase 1
A Safety Study of SGN-CD19A for Leukemia and Lymphoma Start of enrollment: 2013 Feb 01
Completed
Phase 1
Brentuximab Vedotin + Re-induction Chemotherapy for AML Start of enrollment: 2013 May 01
Completed
Phase 1
Sulindac for Patients With AML Start of enrollment: 2014 Jan 01
Withdrawn
Phase 2
A Safety Study of SGN-CD33A in AML Patients Start of enrollment: 2013 Jul 01
Completed
Phase 1
Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients Start of enrollment: 2013 Jul 19
Completed
Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2013 Nov 01
Completed
Phase 1
A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis Start of enrollment: 2014 Jul 16
Active, not recruiting
Phase 1, Phase 2
Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML Start of enrollment: 2015 Jan 01
Terminated
Phase 1
Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML Start of enrollment: 2015 Dec 01
Completed
Phase 2
Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia Start of enrollment: 2016 Sep 01
Withdrawn
Phase 1
DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission Start of enrollment: 2017 Jun 01
Recruiting
Phase 2
IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation Start of enrollment: 2018 Jul 17
Completed
Phase 1
IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation Start of enrollment: 2019 Jan 16
Completed
Phase 1
A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia Start of enrollment: 2018 Dec 20
Terminated
Phase 1, Phase 2
Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia Start of enrollment: 2019 Dec 06
Active, not recruiting
Phase 2
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML Start of enrollment: 2021 May 20
Recruiting
Phase 2
FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies Start of enrollment: 2021 Jun 14
Recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

1 citations
Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial.
Eunice S Wang, Ghayas C Issa, Harry P Erba, Jessica K Altman, Pau Montesinos
The Lancet. Oncology. 2024-10-01
1 citations
Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Bijal Shah, Ryan J Mattison, Ramzi Abboud, Peter Abdelmessieh, Ibrahim Aldoss
Journal of the National Comprehensive Cancer Network. 2024-10-01
5 citations
Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome.
Courtney D DiNardo, Gail J Roboz, Justin M Watts, Yazan F Madanat, Gabrielle T Prince
Blood Advances. 2024-08-13

Journal Articles

Effectiveness of Integrated Palliative and Oncology Care for Patients with Acute Myeloid Leukemia
Areej El-Jawahri, Thomas W Leblanc, Selina M Luger, Bhavana Bhatnagar, Alison R Walker, Amir T Fathi, Andrew M Brunner, Gabriela S Hobbs, Jennifer S Temel, JAMA Oncology
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
Daniel A Pollyea, Amir T Fathi, Geoffrey L Uy, Robert K Stuart, Mikkael A Sekeres, Courtney D DiNardo, Alice S Mims, Eyal C Attar, Richard M Stone, Hagop M Kantarjian,..., The New England Journal of Medicine
A Phase 1 Trial of Vadastuximab Talirine Combined with Hypomethylating Agents in Patients with CD33 Positive AML
Eytan M Stein, Anand Jillella, Anthony S Stein, Amir T Fathi, Roland B Walter, Jeffrey E Lancet, Tibor J Kovacsovics, Anjali S Advani, Phoenix A Ho, Dale Bixby, Blood

Abstracts/Posters

Ivosidenib (AG-120) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study
Amir T. Fathi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myelo...
Amir T. Fathi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Complex Polyclonal Resistance Mechanisms to Ivosidenib Monotherapy in IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia Revealed By Single Cell Sequencing Anal...
Amir T. Fathi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Molecular Mechanisms Mediating Relapse Following Ivosidenib Monotherapy in Patients with IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia
Amir T. Fathi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Bone Marrow Morphologic Findings in Patients Receiving IDH Inhibitor Therapy in Combination with Intensive Induction Chemotherapy: Challenges with Interpretation of th...
Amir T. Fathi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosid...
Amir T. Fathi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

AML: Expert Guidance on Current Standards and New Directions in Patient Care
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Quality of Life and Psychological Distress in Patients with Acute Myeloid Leukemia (AML)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase I Study of the Antibody-Drug Conjugate Brentuximab Vedotin Combined with Re-Induction Chemotherapy in Patients with CD30-Expressing Relapsed/Refractory Acute Mye...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Results from ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
New Therapies for Better Patient Outcomes in Acute Myeloid Leukemia: Integration of Recent Data Sets Into Clinical Practice
60th American Society of Hematology Annual Meeting - 11/30/2018
Hematologic Malignancies and Hematology Update 2013
Harvard Medical School ,Department Of Continuing Education, Boston, Massachusetts - 4/5/2013
Join now to see all

Press Mentions

$ORYZON Presents Preliminary Data from Ongoing Phase Ib FRIDA Trial with Iadademstat plus Gilteritinib in Relapsed/Refractory FLT3-Mut AML Patients at EHA-2024$
ORYZON Presents Preliminary Data from Ongoing Phase Ib FRIDA Trial with Iadademstat plus Gilteritinib in Relapsed/Refractory FLT3-Mut AML Patients at EHA-2024June 14th, 2024
A Beacon of Hope: Exploring Immunotherapy for Bone CancerMay 11th, 2024
Agios to Present Updated Clinical Data from PKR Activator AG-348 at EHAMay 18th, 2017
Join now to see all